Tutelix Update
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Tetratherix Limited has announced the advancement of its Tutelix prostate spacing clinical trial following a successful capital raise. The trial aims to evaluate the safety and effectiveness of Tutelix in creating space during radiation therapy for prostate cancer patients. The company reported promising results from initial studies, indicating that Tutelix maintains its form and does not cause safety issues.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
On 6ix: 6ix.com/news/tutelix-update
Earlier from Tetratherix
- Half Yearly Report and Accounts
- TetraDerm Cohort 1 Results
- Quarterly Activities/Appendix 4C Cash Flow Report
- Executed Henry Schein Agreement
- TetraDerm Cohort 2
Later from Tetratherix
- Precision medicine franchise launch and new revenue
- Successful Completion $15M Placement
- Appendix 4E and Annual Report 2026
Follow Tetratherix into a list and get an email when it puts out news.
Follow Tetratherix